Clinical Trial

Impact of 3D-EIT-Guided Acapella Breathing Training on Lung Ventilation Distribution

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 29, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this randomized clinical trial is to determine whether real-time visual feedback from three-dimensional electrical impedance tomography (3D-EIT) can improve the effects of Acapella breathing exercises in adults recovering from critical illness. 3D-EIT is a noninvasive bedside imaging method that provides real-time information about how ventilation is distributed within the lungs. Participants will be randomly assigned to one of two groups. Both groups will perform a standardized Acapella breathing exercise while 3D-EIT data and vital signs are recorded. Participants in the control group will receive routine verbal and demonstration-based breathing instructions without viewing the EIT images. Participants in the intervention group will receive the same instructions and will also view their own real-time 3D-EIT ventilation images. They will use this visual feedback to adjust their breathing with the goal of increasing ventilation in the dorsal regions of the lungs and/or achieving a more even distribution of ventilation. The main question is whether 3D-EIT-guided visual feedback results in a greater improvement in end-expiratory lung impedance (EELI) after breathing exercise compared with routine instruction alone. The study will also examine changes in regional ventilation distribution, ventilation inhomogeneity, vital signs, breathing discomfort, comfort and tolerance, achievement of the breathing-training target, and adverse events. Approximately 30 participants will be enrolled and randomly assigned in a 1:1 ratio to the two study groups.
Trial Details
NCT Number NCT07733843
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Critical Illness Recovery, Pulmonary Rehabilitation
Enrollment 30 participants
Start Date 2026-07-31
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-03-21 (estimated)
Updated on ClinicalTrials.gov 2026-07-29